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Abstract 
In this report, we describe the case of a patient with splenic marginal zone lymphoma 
(SMZL) who presented with spastic paraplegia as the initial symptom. A 42-year-old male 
developed progressive spastic paraplegia over 4 months. His neurologic examination 
revealed paraplegia with pyramidal syndrome, hypoesthesia below the T1 level, and anal 
hypotonia. Magnetic resonance imaging (MRI) of the spinal cord revealed an extensive 
high-intensity signal in T2-weighted sequences and swelling involving the thoracic 
region and conus medullaris. A laboratory test revealed presence of the serum M 
component. Abdominal computed tomography images showed moderate splenomegaly. 
Abnormal lymphocytes of B-cell lineage markers (CD19+, CD20+, and CD25+; surface 
immunoglobulin κ expression; IgD+ and IgM+) were found in the peripheral blood, 
cerebrospinal fluid, bone marrow and spleen. Splenectomy confirmed the SMZL 
diagnosis. After the completion of chemotherapy, the patient was in complete remission, 
and spinal MRI findings were normal. Intramedullary spinal cord involvement in SMZL is 
extremely rare, and, to the best of our knowledge, this is the first case of SMZL with 
intramedullary spinal cord involvement associated with clinical and radiologic signs 
without the involvement of cerebral structures. Spastic paraplegia can be the initial 
presentation of SMZL. 
Introduction 
Splenic marginal zone lymphoma (SMZL) is a well-defined low-grade B-cell non-
Hodgkin’s lymphoma that primarily affects the white and red pulps of the spleen [1]. 
Patients with this disease are typically elderly men, and this tumor usually involves the  
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bone marrow, liver, and splenic hilar lymph nodes [1]. Involvement of the central nervous 
system (CNS) in the initial stage is rare in SMZL, and only a few cases of meningeal 
lymphomatosis as the first manifestation of SMZL have been reported in the literature [2, 
3]. We report on the unique case of a patient with SMZL presenting with spastic 
paraplegia as the initial symptom.  
Case Report 
A 42-year-old male patient with no history of illness was admitted to our hospital because of 
progressive spastic paraplegia over 4 months. In November 2004, he noticed paresthesia in the soles of 
his feet. In February 2005, he developed paresthesia in both hands, spasticity of his legs, and paresthesia 
below the T10 level. Over the next few months, he noted a progressive worsening of spastic paraplegia 
and sensory disturbance at the T1 sensory level. On admission, neurologic examinations revealed 
paraplegia with pyramidal syndrome, hypoesthesia below the T1 level, and anal hypotonia. Other 
examinations showed normal results. WBC count was 5,700/dl, with 46% lymphocytes (19% of which 
were atypical). Viral and bacterial test results and the LDH level were normal. Serum protein 
electrophoresis revealed the presence of an IgM paraprotein. The level of a soluble anti-interleukin-2 
receptor antibody was elevated (3,830 U/ml). The nerve conduction study yielded normal results. Spinal 
cord magnetic resonance imaging (MRI) revealed an extensive high-intensity signal in T2-weighted 
sequences and swelling involving the thoracic region (from T1 to T12) and conus medullaris (fig. 1). 
There was no gadolinium enhancement in T1-weighted sequences. Brain MRI findings were normal. 
Cerebrospinal fluid (CSF) examination showed a high protein level with atypical lymphocytes. Flow 
cytometry of peripheral blood and CSF showed B-lineage markers (CD19+, CD20+, and CD25+; surface 
immunoglobulin κ expression; IgD+ and IgM+, CD5– and CD103–). Abdominal computed 
tomography (CT) images showed moderate splenomegaly (fig. 2). No peripheral lymphadenopathy or 
hepatomegaly was detected. Splenectomy was performed. A histopathological analysis of the spleen 
showed typical white pulp lymphocyte infiltration (fig. 2). The lymphoid cells exhibited the same 
phenotypic B-lymphocyte infiltration as in the peripheral blood, CSF, and bone marrow. The diagnosis 
of SMZL was established. Intrathecal cytarabine, methotrexate, hydrocortisone sodium phosphate, 
systemic fludarabine phosphate, and rituximab were administered.  
Three months after the completion of chemotherapy, the patient was in complete remission, and 
follow-up spinal MRI findings were normal (fig. 1). Five years after the diagnosis, the patient remains in 
complete remission and his neurologic examination findings are almost normal.  
Discussion 
We report on the unique case of a patient with SMZL with spinal involvement 
presenting with spastic paraplegia as the initial symptom. In our patient, the rapid 
diagnosis enabled the immediate initiation of chemotherapy, which led to clinical stability 
and radiologic improvements.  
SMZL is a rare but distinctive and well-defined low-grade B-cell non-Hodgkin’s 
lymphoma that primarily affects the white and red pulps of the spleen [1]. The clinical 
symptoms of SMZL are nonspecific; e.g. fatigue, moderate anemia, abdominal symptoms 
due to splenomegaly and lymphocytosis as incidental findings. CNS involvement is a 
common complication of high-grade lymphoma, but is rare in mature B-cell malignancies 
such as SMZL [4]; however, it can occur in the advanced stage [4, 5]. Our patient 
presented with spastic paraplegia as the initial symptom. The CNS involvements in 
SMZL, as previously reported, were leptomeningeal involvement [2–4] and intracerebral 
tumor [5]. Of the four previously reported cases of patients with SMZL,only two patients 
showed neurological symptoms as the initial manifestations [2, 3]. These two patients 
presented with leptomeningeal involvement, and the clinical manifestations of these two  
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cases were polyradiculoneuropathy [2] and papilledema [3]. Our patient showed 
intramedullary spinal cord involvement as determined by MRI. In the four reported cases 
of SMZL with CNS involvement, three [3–5] showed abnormal MRI findings. The patient 
of Bruna et al. [3] showed tumoral infiltration in both the optic nerves and cervicodorsal 
meninges. That of Gotlib et al. [4] showed multiple meningeal nodules around the 
posterior fossa. That of Thoennissen et al. [5] showed multiple intracerebral tumor 
lesions. Intramedullary spinal cord involvement in SMZL is extremely rare, and, to the 
best of our knowledge, this is the first case of SMZL with intramedullary spinal cord 
involvement associated with clinical and radiologic signs without the involvement of 
cerebral structures.  
It is uncertain why clinical CNS involvement is rare in B-cell lymphoproliferative 
disorders. Yamazaki et al. [2] suggested that the low expression level of adhesion 
receptors of B-lymphocytes might explain the low frequency of meningeal involvement.  
Our patient is still alive after 5 years and imaging studies confirmed him to be in 
complete remission. SMZL is generally considered to be of low grade, with some reported 
patients having a long-term survival, while others have an aggressive course with death 
within 1 year of diagnosis [1]. In the reported SMZL cases with meningeal involvement 
[3, 4], the outcomes were not good. Bruna et al. [4] suggested that CNS involvement 
indicates a poor prognosis. Further studies on the clinical and morphologic characteristics 
of SMZL are required to prevent recurrence and disease-related death. CNS involvement 
associated with SMZL is rare, and symptomatic involvement is even more so. Thus, 
physicians should take into account the possibility of CNS invasion in SMZL or other 
mature B-cell proliferative malignancies when patients present with neurologic 
manifestations. 
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Fig. 1. a, b Sagittal T2-weighted MR images showing enlargement of the thoracic cord at the T1–T12 
levels and conus medullaris associated with high signal intensity. c Axial T2-weighted MR image 
showing central signal intensity abnormality in cord at the T4 level. d, e Sagittal T2-weighted MR 
images after treatment. Abnormal lesions have completely disappeared. f Axial T2-weighted MR image 
after treatment. Abnormal lesions have completely disappeared. 
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Fig. 2. a Abdominal CT scan showing moderate splenomegaly. b Spleen section showing prominent 
white pulp infiltration by lymphocytes with marginal zone expansion (HE staining; original 
magnification ×40). 
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